Teva Introduces Ropinirole Hydrochloride Tablets
North Wales, Pennsylvania, May 7, 2008 – Teva Pharmaceuticals is pleased to announce the introduction and availability of Ropinirole Hydrochloride Tablets. This product is AB rated and bioequivalent to Requip®* Tablets. Ropinirole HCl Tablets are available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg strengths, in bottle sizes of 100.

“Generic pharmaceuticals are playing an increasingly important role in healthcare cost containment,” states John Denman, V.P. Sales and Marketing. “Teva Pharmaceuticals continues to lead the way with timely new product launches.”

Teva Pharmaceuticals, located in North Wales, Pennsylvania, is the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.‡

* Requip® is a registered trademark of SmithKline Beecham P.L.C.
‡ Data on file, Teva USA.